<PAGE>
<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
AMENDMENT NO. 1 TO FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended JULY 31, 1998
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________________ to _______________________
Commission file number: 0-13649
COOPER LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
DELAWARE 94-2563513
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
160 BROADWAY, NEW YORK, NEW YORK 10038
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (212) 791-5362
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
As of September 8, 1998, there were 2,126,265 outstanding shares of the
issuer's Common Stock, $.10 par value.
<PAGE>
<PAGE>
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its Quarterly Report Pursuant to
Section 13 or 15(d) of the Seceurities Exchange Act of 1934 on Form 10-Q for the
quarterly period ended July 31, 1998, as set forth in the pages attached hereto:
Condensed Statements of Consolidated Cash Flows.
2
<PAGE>
<PAGE>
COOPER LIFE SCIENCES, INC. AND SUBSIDIARIES
CONDENSED STATEMENTS OF CONSOLIDATED CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
<TABLE>
<CAPTION>
Nine Months Ended
July 31,
---------------------
1998 1997
------ ------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 36,979 $ 10,344
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
(Gain) on sale of marketable securities (38,909) (10,384)
Non cash compensation charge and other -- 80
(Increase) in deferred taxes (925) --
Changes in assets and liabilities:
Decrease in prepaid expenses and other 78 78
Decrease in accounts payable and other
accrued liabilities (1,312) (88)
-------- --------
Net cash provided by (used in) (4,089) 30
operating activities -------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of The Cooper Companies, Inc.
and Executone Information Systems, Inc.
common stock 44,617 19,152
-------- --------
Net cash provided by investing activities 44,617 19,152
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Acquisition of treasury stock -- (625)
Proceeds from exercise of common stock options -- 3
-------- --------
Net cash used in financing activities -- (622)
-------- --------
Net increase in cash and cash equivalents 40,528 18,560
Cash and cash equivalents - beginning 25,887 471
-------- --------
Cash and cash equivalents - ending $ 66,415 $ 19,031
======== ========
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash used to pay taxes $ 4,159 $ --
</TABLE>
SEE NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
3
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COOPER LIFE SCIENCES, INC.
--------------------------
(Registrant)
Date: September 17, 1998 By: /s/ Steven Rosenberg
------------------- ---------------------
STEVEN ROSENBERG
VICE PRESIDENT AND CHIEF
FINANCIAL OFFICER
4
